-- Curis



) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

Highlights from the ratings report include:

  • CRIS's very impressive revenue growth greatly exceeded the industry average of 3.0%. Since the same quarter one year prior, revenues leaped by 13849.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • CRIS has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 9.97, which clearly demonstrates the ability to cover short-term cash needs.
  • CURIS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CURIS INC reported poor results of -$0.13 versus -$0.06 in the prior year. This year, the market expects an improvement in earnings (-$0.10 versus -$0.13).
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CURIS INC's return on equity significantly trails that of both the industry average and the S&P 500.


Curis, Inc., a drug discovery and development company, engages in the research and development of cancer therapeutics. Curis has a market cap of $372.2 million and is part of the

health care

sector and


industry. Shares are down 1.5% year to date as of the close of trading on Tuesday.

You can view the full

Curis Ratings Report

or get investment ideas from our

investment research center


-- Written by a member of TheStreet RatingsStaff